Regeneron’s rare disease drug outshone placebo in a phase 2 study, warding off the majority of new bone formation in adults with a disorder that causes the body’s soft tissues to turn into bone. Full results from the trial will form the backbone of the drug’s regulatory submission.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,